Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Accumulated Expenses (2020 - 2026)

Nautilus Biotechnology has reported Accumulated Expenses over the past 7 years, most recently at $3.3 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $3.3 million for Q1 2026, up 7.55% from a year ago — trailing twelve months through Mar 2026 was $3.3 million (up 7.55% YoY), and the annual figure for FY2025 was $3.2 million, up 24.69%.
  • Accumulated Expenses reached $3.3 million in Q1 2026 per NAUT's latest filing, up from $3.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.3 million in Q3 2023 and bottomed at $2.5 million in Q4 2024.
  • Median Accumulated Expenses over the past 5 years was $3.4 million (2023), compared with a mean of $3.4 million.
  • The largest annual shift saw Accumulated Expenses skyrocketed 136.17% in 2022 before it tumbled 35.41% in 2024.
  • Over 5 years, Accumulated Expenses stood at $3.5 million in 2022, then rose by 11.82% to $3.9 million in 2023, then crashed by 35.41% to $2.5 million in 2024, then rose by 24.69% to $3.2 million in 2025, then increased by 4.03% to $3.3 million in 2026.
  • Business Quant data shows Accumulated Expenses for NAUT at $3.3 million in Q1 2026, $3.2 million in Q4 2025, and $3.9 million in Q3 2025.